CA1312030C - Methode pour accroitre le titre d'anticorps - Google Patents

Methode pour accroitre le titre d'anticorps

Info

Publication number: CA1312030C
Authority: CA; Canada
Prior art keywords: cell; growth; culture; accordance; cells
Prior art date: 1987-11-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000581361A

Other languages

English (en)

Inventor

Brian Maiorella

Duane Inlow

William Howarth

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Cetus Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-18

Filing date

1988-10-26

Publication date

1992-12-29

1988-10-26 Application filed by Cetus Corp filed Critical Cetus Corp

1992-12-29 Application granted granted Critical

1992-12-29 Publication of CA1312030C publication Critical patent/CA1312030C/fr

2009-12-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 52
210000004027 cell Anatomy 0.000 claims abstract description 147
210000004408 hybridoma Anatomy 0.000 claims abstract description 45
238000004113 cell culture Methods 0.000 claims abstract description 35
230000010261 cell growth Effects 0.000 claims abstract description 32
230000001965 increasing effect Effects 0.000 claims abstract description 31
230000014509 gene expression Effects 0.000 claims abstract description 30
239000001963 growth medium Substances 0.000 claims abstract description 16
230000012010 growth Effects 0.000 claims description 56
235000002639 sodium chloride Nutrition 0.000 claims description 34
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
239000002609 medium Substances 0.000 claims description 21
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 20
210000004962 mammalian cell Anatomy 0.000 claims description 19
239000011780 sodium chloride Substances 0.000 claims description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 14
239000008103 glucose Substances 0.000 claims description 14
229940001447 lactate Drugs 0.000 claims description 14
102000004169 proteins and genes Human genes 0.000 claims description 14
108090000623 proteins and genes Proteins 0.000 claims description 14
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
235000019270 ammonium chloride Nutrition 0.000 claims description 12
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 11
229920001451 polypropylene glycol Polymers 0.000 claims description 11
239000001540 sodium lactate Substances 0.000 claims description 11
229940005581 sodium lactate Drugs 0.000 claims description 11
235000011088 sodium lactate Nutrition 0.000 claims description 11
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
229910021529 ammonia Inorganic materials 0.000 claims description 6
239000001103 potassium chloride Substances 0.000 claims description 5
235000011164 potassium chloride Nutrition 0.000 claims description 5
229930091371 Fructose Natural products 0.000 claims description 4
239000005715 Fructose Substances 0.000 claims description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
239000006143 cell culture medium Substances 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
229930195725 Mannitol Natural products 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
239000000594 mannitol Substances 0.000 claims description 3
235000010355 mannitol Nutrition 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
235000011148 calcium chloride Nutrition 0.000 claims 1
235000011147 magnesium chloride Nutrition 0.000 claims 1
239000000047 product Substances 0.000 abstract description 37
150000003839 salts Chemical class 0.000 abstract description 23
229920005862 polyol Polymers 0.000 abstract description 9
150000003077 polyols Chemical class 0.000 abstract description 9
230000002503 metabolic effect Effects 0.000 abstract description 6
210000004102 animal cell Anatomy 0.000 abstract description 4
238000012258 culturing Methods 0.000 abstract description 4
238000013459 approach Methods 0.000 abstract description 3
230000003247 decreasing effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 description 31
230000000694 effects Effects 0.000 description 23
238000007792 addition Methods 0.000 description 21
230000004927 fusion Effects 0.000 description 14
239000000523 sample Substances 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
238000012360 testing method Methods 0.000 description 11
239000002158 endotoxin Substances 0.000 description 9
230000016784 immunoglobulin production Effects 0.000 description 8
229920006008 lipopolysaccharide Polymers 0.000 description 8
230000035899 viability Effects 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
238000000855 fermentation Methods 0.000 description 7
230000004151 fermentation Effects 0.000 description 7
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
201000000050 myeloid neoplasm Diseases 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000012679 serum free medium Substances 0.000 description 7
241001529936 Murinae Species 0.000 description 6
230000007423 decrease Effects 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
210000002966 serum Anatomy 0.000 description 5
210000004988 splenocyte Anatomy 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
210000004754 hybrid cell Anatomy 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
229920001983 poloxamer Polymers 0.000 description 4
239000004017 serum-free culture medium Substances 0.000 description 4
210000004748 cultured cell Anatomy 0.000 description 3
230000034994 death Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
229960000448 lactic acid Drugs 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000019522 cellular metabolic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000009668 clonal growth Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
238000005457 optimization Methods 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
238000011282 treatment Methods 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
244000166550 Strophanthus gratus Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229950011321 azaserine Drugs 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
238000010923 batch production Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000010364 biochemical engineering Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
-1 for example Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
238000003165 hybrid screening Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000005286 illumination Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000020939 nutritional additive Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
229960003343 ouabain Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004091 panning Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940116540 protein supplement Drugs 0.000 description 1
235000005974 protein supplement Nutrition 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
201000002341 thymus lymphoma Diseases 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
239000007160 ty medium Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA000581361A 1987-11-18 1988-10-26 Methode pour accroitre le titre d'anticorps Expired - Lifetime CA1312030C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12201587A	1987-11-18	1987-11-18
US122,015		1987-11-18

Publications (1)

Publication Number	Publication Date
CA1312030C true CA1312030C (fr)	1992-12-29

Family

ID=22400058

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000581361A Expired - Lifetime CA1312030C (fr)	1987-11-18	1988-10-26	Methode pour accroitre le titre d'anticorps

Country Status (3)

Country	Link
AU (1)	AU2805989A (fr)
CA (1)	CA1312030C (fr)
WO (1)	WO1989004867A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5183754A (en) *	1988-10-04	1993-02-02	Mitsui Toatsu Chemicals, Incorporated	Method for production of human tissue type plasminogen activator
US5856179A (en)	1994-03-10	1999-01-05	Genentech, Inc.	Polypeptide production in animal cell culture
US5721121A (en) *	1995-06-06	1998-02-24	Genentech, Inc.	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) *	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
US6656466B1 (en)	1995-06-06	2003-12-02	Genetech, Inc.	Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
ATE490787T1 (de)	2003-07-15	2010-12-15	Chugai Pharmaceutical Co Ltd	Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
EP1688432B1 (fr)	2003-10-09	2011-08-03	Chugai Seiyaku Kabushiki Kaisha	Solution stabilisee a concentration elevee en igm
EP1686137A4 (fr)	2003-10-09	2009-10-28	Chugai Pharmaceutical Co Ltd	Methode de stabilisation de solution proteinique
US20110117087A1 (en)	2009-10-26	2011-05-19	Reinhard Franze	Method for the production of a glycosylated immunoglobulin
US10961500B1 (en) *	2019-04-23	2021-03-30	Regeneron Pharmaceuticals, Inc.	Cell culture medium for eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1206433A (fr) *	1982-08-06	1986-06-24	Channing R. Robertson	Production de produits biologiques a l'aide de cellules au repos
US4724206A (en) *	1984-02-13	1988-02-09	Damon Biotech, Inc.	Protein production using hypertonic media
GB8516415D0 (en) *	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells

1988
- 1988-10-26 CA CA000581361A patent/CA1312030C/fr not_active Expired - Lifetime
- 1988-11-14 WO PCT/US1988/004068 patent/WO1989004867A1/fr not_active Ceased
- 1988-11-14 AU AU28059/89A patent/AU2805989A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1989004867A1 (fr)	1989-06-01
AU2805989A (en)	1989-06-14

Publication	Publication Date	Title
US6238891B1 (en)	2001-05-29	Method of increasing product expression through solute stress
EP0014519B1 (fr)	1983-04-06	Lignées de cellules, procédé pour leur préparation et procédé pour la production d'anticorps
US4594325A (en)	1986-06-10	High fusion frequency fusible lymphoblastoid cell line
CA1312030C (fr)	1992-12-29	Methode pour accroitre le titre d'anticorps
EP0292965A2 (fr)	1988-11-30	Lignée de cellules humaines et triomes, anticorps et cellules transformées
Siraganian et al.	1983	[2] Methods of enhancing the frequency of antigen-specific hybridomas
Kovář et al.	1987	Iron compounds at high concentrations enable hybridoma growth in a protein-free medium
JPS5863385A (ja)	1983-04-15	免疫系由来の細胞用培地
US4198479A (en)	1980-04-15	Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
GB2251249A (en)	1992-07-01	High density media for mammalian cell culture
HU191984B (en)	1987-04-28	Process for preparing hybridomes and by means thereof antibodies
Shirahata et al.	1998	Cell hybridization, hybridomas, and human hybridomas
US4675295A (en)	1987-06-23	Process for producing subculturable lymphokine-producing human T cell hybridomas
EP0107528B1 (fr)	1988-09-07	Lignée de cellules plasmacytoides humaines non-secrétoires
JPH03254679A (ja)	1991-11-13	新規細胞株
KR930006117B1 (ko)	1993-07-07	동물세포 배양용 고농도 배지 및 배양공정
US11186858B1 (en)	2021-11-30	Methods for increasing biosimilarity
Klinman et al.	1981	Dialyzable serum components can support the growth of hybridoma cell lines in vitro
US11254964B1 (en)	2022-02-22	Cell culture methods for increased cell viability
EP0295605B1 (fr)	1994-09-07	Facteur stimulateur de la production d'anticorps produit par les cellules lymphoblastoides B et procédé pour la production d'anticorps avec ce facteur stimulateur
Holmlund et al.	1992	Growth and metabolism of recombinant CHO cell‐lines in serum‐free medium containing derivatives of glutamine
SU1640157A1 (ru)	1991-04-07	Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к ДНК-зависимой РНК-полимеразе бактериофага Т7
JPS6163283A (ja)	1986-04-01	ハイブリ−ド−マの培養方法
KR880002318B1 (ko)	1988-10-22	무혈청 배지
SU1495374A1 (ru)	1989-07-23	Штамм культивируемых клеток животных MUS мUSсULUS - продуцент ростстимулирующих факторов гибридом

Legal Events

Date	Code	Title	Description
2008-12-29	MKLA	Lapsed